tiprankstipranks
Oragenics Inc (OGEN)
NYSE MKT:OGEN

Oragenics (OGEN) Stock Price & Analysis

937 Followers

OGEN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.26 - $7.74
Previous Close$1.4
Volume25.71K
Average Volume (3M)87.56K
Market Cap
$6.27M
Enterprise Value$1.02M
Total Cash (Recent Filing)$5.77M
Total Debt (Recent Filing)$517.76K
Price to Earnings (P/E)-0.3
Beta1.09
May 13, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-4.67
Shares Outstanding2,569,385
10 Day Avg. Volume53,922
30 Day Avg. Volume87,562
Standard Deviation0.28
R-Squared0.00299
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.74
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue27.20
Enterprise Value/Gross Profit7.79
Enterprise Value/Ebitda-0.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

OGEN FAQ

What was Oragenics Inc’s price range in the past 12 months?
Oragenics Inc lowest stock price was $1.26 and its highest was $7.74 in the past 12 months.
    What is Oragenics Inc’s market cap?
    Currently, no data Available
    When is Oragenics Inc’s upcoming earnings report date?
    Oragenics Inc’s upcoming earnings report date is May 13, 2024 which is in 45 days.
      How were Oragenics Inc’s earnings last quarter?
      Oragenics Inc released its earnings results on Aug 14, 2023. The company reported -$1.507 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.507.
        Is Oragenics Inc overvalued?
        According to Wall Street analysts Oragenics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Oragenics Inc pay dividends?
          Oragenics Inc does not currently pay dividends.
          What is Oragenics Inc’s EPS estimate?
          Oragenics Inc’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Oragenics Inc have?
          Oragenics Inc has 4,480,693 shares outstanding.
            What happened to Oragenics Inc’s price movement after its last earnings report?
            Oragenics Inc reported an EPS of -$1.507 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.627%.
              Which hedge fund is a major shareholder of Oragenics Inc?
              Currently, no hedge funds are holding shares in OGEN
              ---

              Oragenics Stock Smart Score

              N/A
              Not Ranked
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Company Description

              Oragenics Inc

              Oragenics, Inc. is a biopharmaceutical company, which focuses on the development of novel antibiotics and treatments against infectious disease and oral mucositis. Its technology and pipeline is comprised of lantibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Lineage Therap
              Vericel
              Aldeyra Therapeutics
              Bioxcel Therapeutics
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis